Jing An

List of Publications by Year
in descending order

38 papers	671 citations	759233 12 h-index	580821 25 g-index
38 all docs	38 docs citations	38 times ranked	1096 citing authors

#	Article	IF	Citations
1	A fragment integrational approach to GPCR inhibition: Identification of a high affinity small molecule CXCR4 antagonist. European Journal of Medicinal Chemistry, 2022, 231, 114150.	5.5	3
2	Difficult to evaluate the effect of remimazolam. Journal of Anesthesia, 2022, , 1.	1.7	1
3	A case of mesenchymal hamartoma of the chest wall in neonates. Asian Journal of Surgery, 2022, , .	0.4	0
4	A giant rhabdomyosarcoma of the neck in neonates. Asian Journal of Surgery, 2022, , .	0.4	0
5	Trends in application of advancing computational approaches in GPCR ligand discovery. Experimental Biology and Medicine, 2021, 246, 1011-1024.	2.4	5
6	A new class of Î±-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities. European Journal of Medicinal Chemistry, 2021, 215, 113267.	5.5	13
7	A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys. Stem Cell Research and Therapy, 2021, 12, 17.	5.5	4
8	Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer. RSC Medicinal Chemistry, 2020, 11, 125-131.	3.9	6
9	Chemical mutagenesis of a GPCR ligand: Detoxifying â€œinflammo-attractionâ€•to direct therapeutic stem cell migration. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31177-31188.	7.1	10
10	Bivalent Ligand Aiming Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Dimers in Opioid Enhanced HIV-1 Entry. ACS Medicinal Chemistry Letters, 2020, 11, 2318-2324.	2.8	7
11	Design, synthesis, and biological characterization of a new class of symmetrical polyamine-based small molecule CXCR4 antagonists. European Journal of Medicinal Chemistry, 2020, 200, 112410.	5.5	9
12	Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics. Journal of Cancer, 2020, 11, 3454-3466.	2.5	21
13	Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors. Experimental Biology and Medicine, 2020, 245, 477-485.	2.4	9
14	LAIR-1 suppresses cell growth of ovarian cancer cell via the PI3K-AKT-mTOR pathway. Aging, 2020, 12, 16142-16154.	3.1	16
15	A novel dimeric CXCR4 antagonist synergizes with chemotherapy in acute myeloid leukaemia by mobilizing leukaemic cells from their associated bone marrow niches. British Journal of Haematology, 2019, 187, e11-e15.	2.5	7
16	Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4. Molecules, 2019, 24, 2928.	3.8	5
17	Pharmacokinetics of a novel microtubule inhibitor mHA11 in rats. Chemico-Biological Interactions, 2019, 308, 235-243.	4.0	2
18	The chemical biology of apoptosis: Revisited after 17 years. European Journal of Medicinal Chemistry, 2019, 177, 63-75.	5.5	26

#	Article	IF	Citations
19	Discovery and Computational Analyses of Novel Small Molecule Zika Virus Inhibitors. Molecules, 2019, 24, 1465.	3.8	8
20	High affinity CXCR4 inhibitors generated by linking low affinity peptides. European Journal of Medicinal Chemistry, 2019, 172, 174-185.	5.5	8
21	Hyperosmotic intraventricular drug delivery of DV1 in the management of intracranial metastatic breast cancer in a mouse model. Journal of Clinical Neuroscience, 2019, 62, 207-211.	1.5	2
22	Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor. Molecules, 2018, 23, 3036.	3.8	7
23	Design, synthesis and characterization of potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities. European Journal of Medicinal Chemistry, 2018, 157, 380-396.	5.5	9
24	LCâ€“MS/MS assay for the determination of a novel D-peptide antagonist of CXCR4 in rat plasma and its application to a preclinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2018, 161, 159-167.	2.8	3
25	Five ETS family members, ELF-1, ETV-4, ETV-3L, ETS-1, and ETS-2 upregulate human leukocyte-associated immunoglobulin-like receptor-1 gene basic promoter activity. Aging, 2018, 10, 1390-1401.	3.1	9
26	Discovery of small molecule inhibitors of the Wnt/Î²-catenin signaling pathway by targeting Î²-catenin/Tcf4 interactions. Experimental Biology and Medicine, 2017, 242, 1185-1197.	2.4	65
27	Design, synthesis, and biological characterization of novel PEG-linked dimeric modulators for CXCR4. Bioorganic and Medicinal Chemistry, 2016, 24, 5393-5399.	3.0	12
28	Enhancement of Radiation Sensitivity in Lung Cancer Cells by a Novel Small Molecule Inhibitor That Targets the Î²-Catenin/Tcf4 Interaction. PLoS ONE, 2016, 11, e0152407.	2.5	19
29	Biomodification of PCL Scaffolds with Matrigel, HA, and SR1 EnhancesDe NovoEctopic Bone Marrow Formation Induced by rhBMP-2. BioResearch Open Access, 2015, 4, 298-306.	2.6	3
30	Three dimensionalde novomicro bone marrow and its versatile application in drug screening and regenerative medicine. Experimental Biology and Medicine, 2015, 240, 1029-1038.	2.4	5
31	Convenient Synthesis of Toxoflavin that Targets Î²â€Catenin/Tcf4 Signaling Activities. Journal of Heterocyclic Chemistry, 2014, 51, 594-597.	2.6	8
32	Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis. Current Topics in Medicinal Chemistry, 2014, 14, 1574-1589.	2.1	45
33	A synthetic bivalent ligand of CXCR4 inhibits HIV infection. Biochemical and Biophysical Research Communications, 2013, 435, 646-650.	2.1	30
34	A Novel Synthetic Bivalent Ligand To Probe Chemokine Receptor CXCR4 Dimerization and Inhibit HIV-1 Entry. Biochemistry, 2012, 51, 7078-7086.	2.5	33
35	Drug Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4). Journal of Medicinal Chemistry, 2012, 55, 977-994.	6.4	102
36	Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus and<scp>d</scp>-Amino Acid-Containing Chemokine. Journal of Virology, 2007, 81, 11489-11498.	3.4	20

#	Article	IF	Citations
37	SMM-Chemokines: A Class of Unnatural Synthetic Molecules as Chemical Probes of Chemokine Receptor Biology and Leads for Therapeutic Development. Chemistry and Biology, 2006, 13, 69-79.	6.0	30
38	Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with d-Peptides Derived from Chemokines. Journal of Biological Chemistry, 2002, 277, 17476-17485.	3.4	109